
Silk Road Medical, Inc Revenue | SILK
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Silk Road Medical, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 M | 139 M | 101 M | 75.2 M | 63.4 M | 34.6 M | 14.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | 14.3 M | 86.4 M |
Quarterly Revenue Silk Road Medical, Inc
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.2 M | 48.5 M | - | 44.4 M | 45.3 M | 40.1 M | - | 37.4 M | 33.2 M | 28 M | - | 24.7 M | 26.5 M | 22.1 M | 21.1 M | 20.1 M | 15.1 M | 18.9 M | 18.6 M | 17 M | 14.9 M | 12.8 M | 11.5 M | 9.61 M | 7.77 M | 5.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.2 M | 5.71 M | 25 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
3.44 B | $ 64.0 | 7.26 % | $ 9.72 B | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 44.68 | 0.06 % | $ 66.1 B | ||
|
Cognyte Software Ltd.
CGNT
|
400 M | $ 8.7 | 0.06 % | $ 634 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 14.61 | 13.03 % | $ 414 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 45.18 | 3.31 % | $ 1.4 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 4.3 | 1.63 % | $ 268 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 16.08 | 0.75 % | $ 576 M | ||
|
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Electromed
ELMD
|
73.8 M | $ 27.86 | 1.05 % | $ 230 M | ||
|
Establishment Labs Holdings
ESTA
|
211 M | $ 65.58 | 3.69 % | $ 1.94 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.73 | 0.32 % | $ 50.1 B | ||
|
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 5.57 | 0.43 % | $ 753 M | ||
|
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.9 | 0.69 % | $ 63.9 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 15.88 | 2.25 % | $ 1.22 B | ||
|
Inogen
INGN
|
349 M | $ 5.23 | 2.75 % | $ 139 M | ||
|
InMode Ltd.
INMD
|
370 M | $ 14.19 | 0.21 % | $ 917 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 68.81 | 0.59 % | $ 2.02 B | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.63 | 2.51 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 85.2 | 0.08 % | $ 1.08 B | ||
|
AxoGen
AXGN
|
225 M | $ 43.32 | 0.48 % | $ 1.99 B | ||
|
Align Technology
ALGN
|
4.03 B | $ 145.63 | 4.36 % | $ 10.6 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 7.08 | 0.28 % | $ 84.7 M | ||
|
Sientra
SIEN
|
25.1 M | - | -16.59 % | $ 10.3 M | ||
|
Medtronic PLC
MDT
|
36.4 B | $ 88.51 | 0.32 % | $ 113 B | ||
|
MiMedx Group
MDXG
|
419 M | $ 4.71 | 0.1 % | $ 696 M | ||
|
Surgalign Holdings
SRGA
|
82 M | - | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | ||
|
Myomo
MYO
|
40.9 M | $ 1.67 | 1.83 % | $ 69.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
13 M | $ 0.66 | 0.45 % | $ 42.8 M | ||
|
InspireMD
NSPR
|
8.98 M | $ 0.7 | 0.37 % | $ 45 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 9.16 | 0.11 % | $ 363 M | ||
|
Outset Medical
OM
|
119 M | $ 3.13 | 1.29 % | $ 47.6 K | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 135.78 | 0.01 % | $ 9.55 B | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 5.6 | 1.66 % | $ 169 M | ||
|
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M | ||
|
Quanterix Corporation
QTRX
|
139 M | $ 3.18 | 0.63 % | $ 136 M | ||
|
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | ||
|
AVITA Medical
RCEL
|
71.6 M | $ 11.58 | 5.75 % | $ 323 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.83 | 1.37 % | $ 116 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 1.87 | 5.06 % | $ 5.19 M | ||
|
Accuray Incorporated
ARAY
|
402 M | $ 0.22 | 0.4 % | $ 27 M | ||
|
Smith & Nephew plc
SNN
|
4.56 B | $ 26.68 | 0.02 % | $ 23.1 B | ||
|
Inari Medical
NARI
|
494 M | - | - | $ 4.23 B |